Condition: Colitis · Diarrhea Caused by Antitumor Drugs · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.
This description comes directly from the study's public registry record.
Wiam Belkaid, PhD · 514-836-3273 · wiam.belkaid.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Universite de Montreal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07196410